CSL Behring develops therapies to treat rare and serious conditions as if our patients’ lives depended on them – because they do.
Around the Around the world, CSL Behring brings life-saving and life-enhancing therapies to people with primary immune deficiencies, bleeding disorders (including haemophilia, congenital fibrinogen deficiency and von Willebrand disease), hereditary angioedema,certain neurological disorders, inherited respiratory disease and other serious conditions. Our products are also used to prevent haemolytic disease in newborns, speed recovery after heart surgery, prevent infection in people undergoing solid organ transplants, and to help victims of shock and burns to recover faster.
We listen carefully to the concerns of the patients and caregivers we serve and then work to address their needs. Not only do we provide safe and effective products aimed at delivering a better quality of life, CSL Behring also offers programs and educational tools that help patients and families manage the daily challenges of living with a chronic condition. We also collaborate with patient groups and policy makers around the world to advocate for patient access to care.
CSL Behring has a long history of manufacturing innovative products in state-of-the-art facilities. We use the most sophisticated methods available and meet or exceed stringent international safety and quality standards. Each step of our manufacturing process from plasma donor to patient reflects the company’s unyielding commitment to ensuring its products are safe.
We are a global leader in biotherapies, with substantial markets in the US, Europe, Latin America, the Middle East, and Japan. CSL Behring is committed to maintaining a reliable and consistent product supply, while continuing to expand our pipeline of new and improved plasma and recombinant therapies, by using cost-effective, high-yield manufacturing processes and efficient operations.
Headquartered in King of Prussia, Pennsylvania (US), CSL Behring operates manufacturing plants in Kankakee, Illinois (US), Bern (Switzerland), Marburg (Germany), and in Melbourne, Australia. Regional sales and distribution centres are located throughout the world.CSL Behring is committed to saving lives and improving the quality of life for people with rare and serious diseases worldwide.
Major Expansion underway in Marburg
Scheduled to be completed in 2014, a new production facility (M240) being built in Marburg is part of a major project to expand production, filling, freeze-drying and packaging facilities to increase manufacturing capacity for specialty products.
At the foundation stone ceremony on 15 February 2013 were (from left) Axel Lahfeld (Project Lead M240), Dr. Reiner Laske (Head of Quality, Marburg), Dr. Johannes Kraemer (Head of Engineering, Marburg), Dr. Roland Martin (Site Manager, CSL Behring GmbH, Marburg), Mary Sontrop (CSL, Executive Vice President Operations) and Dr. Anita Kohl-Truenbenbach (Head of Production, Marburg). The ceremony ended with three symbolic blows with hammers by the group.
Better lives for Ricky and Mackenzie
||Our lives were turned upside down when both our children were diagnosed with an immune disorder called Common Variable Immune Deficiency. We were terrified and saddened by a disease we never heard of and for which there is no cure. We were given a glimmer of hope when told there is something that can help them lead a better quality of life – made from human plasma. “Is that safe?” we wondered. “Could they contract another disease from it?” But we had to explore the possibility.|
Soon after Ricky (age 15) and Mackenzie (age 11) started receiving immune globulin therapy, we saw remarkable changes in them! When CSL Plasma heard our story and asked if we would participate in the Adopt-a-Patient program in their Akron, Ohio plasma collection centre, we were eager to meet the people saving our children’s lives. In that first visit, Ricky and Mackenzie spoke to the donors and employees from their hearts with tears in eyes, thanking them for saving their lives. We shared hugs, tears, smiles and laughter with the donors and employees telling them, all of them, what an important role each of them plays. And seeing for ourselves the process of how plasma is collected, processed, and made safe, put our fears at ease.
We have since been back several times. Speaking to the donors and employees, and sharing our hearts and lives with theirs, is the most profound beautiful feeling of love we have ever experienced. Knowing that strangers from all walks of life are contributing to our children’s future is such a surreal experience; and one that is hard to put into words.
There is a quote I came across when Ricky and Mackenzie were diagnosed, “If you have reached the end of all light that you have known, and you are about to step into the darkness of the unknown, faith can do one of two things. Either you will step on solid ground or you will be taught to fly.” With the Adopt-a-Patient program at CSL, we have full faith that we were taught to fly, all of us, together as one big family.
The Pasco Family
Facilities at Broadmeadows, Australia
In the bulk manufacturing area in the Privigen® facility at Broadmeadows in Melbourne, Shift Leader William Fenech checks the ion exchange column that will be used to purify immunoglobulin G (IgG). Construction of the plant is now complete and the commissioning process is under way. This 15 million gram capacity facility is due to become fully operational by 2016.
Inside CSL’s new cell culture biotechnology facility at Broadmeadows in Melbourne, operators prepare a bioreactor used for culturing mammalian cells.
The recently completed state-of-the-art facility will enhance CSL’s ability to take recombinant products into the clinic and ultimately to patients. Construction was completed on time and on budget and test batches of recombinant proteins have been made in preparation for the production of clinical trial material in the first quarter of 2014.
This new facility will be used for late stage clinical development of new therapies for cancer, bleeding disorders and inflammation.
Helping Carl to follow his dreams
||Pro Supercross racer Carl Schlacht was diagnosed with primary immunodeficiency (PID ) before his first birthday. Today, Carl is a “ChamPIon”.|
Soaring through the air on the back of a motorcycle is a typical day for professional Supercross racer Carl. He competes in this physically demanding sport despite living with PID , a condition he manages with Hizentra®.
CSL Behring recently partnered with Carl for the I am a ChamPIon campaign. As part of this campaign, Carl shares his story with patients, healthcare professionals and the news media as a means of raising awareness of PID while encouraging those with the condition to pursue their dreams despite the challenges that PID can pose.
“Racing off-road motorcycles is definitely a tough, physical sport. I’ve been doing it my whole life. It’s what I love to do,” Carl said. “By partnering with CSL Behring for the I am a ChamPIon campaign, I hope to give kids and young adults with immune system disorders, like myself, the inspiration to be a champion, no matter which dreams they choose to follow.”
“Thank you CSL Behring for helping me to follow my dreams.”
Giving back to our communities
||CSL CEO and Managing Director, Paul Perreault, together with CSL Behring’s United Way Campaign Chairman, Joseph Wells, visited the Freedom Valley YMCA Early Learning Centre in Audubon, Pennsylvania to present a cheque to Jennifer Cavaglia from United Way of Greater Philadelphia and Southern New Jersey.|
Although the United Way Campaign is their largest charitable initiative, CSL Behring and its employees help numerous organisations across the United States from local United Way chapters to patient advocacy groups, food banks and other agencies that provide vital services to people in need.
“Our employees are very generous and they enjoy giving back to their own communities” said Paul. “Employee involvement in determining the organisations we help is important. We seek their input in identifying local organisations needing support. It builds a stronger sense of community and increases our giving efforts. We’re proud of all the ways in which our employees get involved and show they care.”